Diazoxide--an orphan drug?
نویسندگان
چکیده
منابع مشابه
Methadone: An Orphan Drug?
73 Dear Editor: A pharmaceutical product is called “orphan drug” when, although promising or clearly valid from a scientific and therapeutic point of view, it is not profit-bearing and, therefore, not interesting for the pharmaceutical industry. The consequences are the lack of extensive research on its effects, and mainly, the lack of appropriate information to physicians, nurses, and administ...
متن کاملOrphan/rare drug discovery through drug repositioning
There are many, often life-threatening, rare/orphan diseases for which there are few or no therapeutic options. They individually affect few people, but collectively impose very high social and economic burdens. New approaches are bringing big pharma resources to solving the problem through drug repositioning of approved drugs. Advances are being spurred by public and private partnerships, gove...
متن کاملPredictors of orphan drug approval
Results More orphan drugs were developed in the US during the first ten years of the US Orphan Drug Act (1983-1992, N=73) and during the first ten years of the EU Regulation on Orphan Medicinal products (2000-2009, N=112) than in the EU (2000-2009, N=59). Orphan drug approval was strongly associated with previous experiences of the sponsor in obtaining approval for another orphan drug (OR=17.3,...
متن کاملDrug repositioning for orphan diseases
The need and opportunity to discover therapeutics for rare or orphan diseases are enormous. Due to limited prevalence and/or commercial potential, of the approximately 6000 orphan diseases (defined by the FDA Orphan Drug Act as <200 000 US prevalence), only a small fraction (5%) is of interest to the biopharmaceutical industry. The fact that drug development is complicated, time-consuming and e...
متن کاملOptimizing an Orphan Drug Framework for Canada Canada’s Orphan Drug Framework: Lessons from the United States, Europe and Japan
Canada is in the process of developing an orphan drug regulatory framework (the “Canadian Framework”) 1 in which an orphan drug is defined as one targeting a disease that affects fewer than 5 in 10,000 Canadians. The federal government announced the development of the Canadian Framework in 2012. Health Canada has held workshops and announced pilot projects related to the Canadian Framework, but...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Disease in Childhood
سال: 1992
ISSN: 0003-9888,1468-2044
DOI: 10.1136/adc.67.7.980-a